To gain a broader context on our findings, we explored public RNA-seq data from TCGA to evaluate whether the uncoupling between TP53 expression and its downstream targets (e.g., TLR3, CDKN1A, and MDM2) observed in arsenic-transformed prostate epithelial cells also occurs in other tumor types. The gene discussed is MDM2; the disease is neoplasm.